


Data Sheet

Product Name:	Fasudil (Hydrochloride)
Cat. No.:	HY-10341
CAS No.:	105628-07-7
Molecular Formula:	C ₁₄ H ₁₈ N ₃ O ₂ S
Molecular Weight:	327.83
Target:	Autophagy; PKC; ROCK
Pathway:	Autophagy; Cell Cycle/DNA Damage; Epigenetics; Stem Cell/Wnt; TGF-β/Smad
Solubility:	DMSO: ≥ 31 mg/mL



BIOLOGICAL ACTIVITY:

Fasudil (Hydrochloride) is a potent inhibitor of **ROCK-II**, **PKA**, **PKG**, **PKC**, and **MLCK** with **K_i** of 0.33 μM, 1.6 μM, 1.6 μM, 3.3 μM and 36 μM, respectively.

IC₅₀ & Target: **K_i**: 0.33 μM (ROCK-II), 1.6 μM (PKA), 1.6 μM (PKG), 3.3 μM (PKC), 36 μM (MLCK)

In Vitro: Fasudil (Hydrochloride) has vasodilatory action and occupies the adenine pocket of the ATP-binding site of the enzyme^[1]. Fasudil is a class of calcium antagonists. Fasudil produces a competitive inhibition of the Ca²⁺-induced contraction of the depolarized rabbit aorta. Fasudil is able to inhibit contractile responses to KCl, phenylephne (PHE) and prostaglandin (PG) F_{2a}^[2]. Fasudil also exhibits vasodilator actions by inhibition of 5-hydroxytryptamine, noradrenaline, histamine, angiotensin, and dopamine induced spiral strips contraction^[3]. Fasudil induces disorganization of actin stress fiber and cell migration inhibition^[4]. Fasudil inhibits hepatic stellate cells spreading, the formation of stress fibers, and expression of α-SMA with concomitant suppression of cell growth, but does not induce apoptosis. Fasudil suppresses the LPA-induced phosphorylation of ERK1/2, JNK and p38 MAPK^[5].

In Vivo: Fasudil (30 μg) produces an approximate 50% increase in CBF via intra-coronary injection to dogs. Fasudil (0.01, 0.03, 0.1 and 0.3 mg/kg, bolus, i.v.) dose-dependently decreases MBP and increases HR, VBF, CBF, RBF, and FBF. A total dose of 1.0 ng/mL Fasudil increases cardiac output. The infusion of Fasudil i.v. produces a significant fall in MBP, left ventricular systolic pressure and total peripheral resistance with an increase in HR and cardiac output, but without significant changes in right atrial pressure, dP/dt or left ventricular minute work in dogs^[3]. Fasudil administration displays protectable effects on cardiovascular disease and reduces the activation of JNK and attenuates mitochondrial-nuclear translocation of AIF under ischemic injury^[6]. The oral administration of Fasudil (a dosage of 100 mg/kg/day) significantly reduces incidence and mean maximum clinical score of EAE in SJL/J mice immunized with PLP p139-151. Treatment of mice with Fasudil suppresses the proliferative response of splenocytes to the antigen. Oral administration of Fasudil decreases inflammation, demyelination, axonal loss and APP positivein spinal cord of Fasudil-treated mice^[7].

PROTOCOL (Extracted from published papers and Only for reference)

Kinase Assay: ^[1]Cyclic AMP-dependent protein kinase activity is assayed in a reaction mixture containing, in a final volume of 0.2 mL, 50 mM Tris-HCl (pH 7.0), 10 mM magnesium acetate, 2 mM EGTA, 1 μM cyclic AMP or absence of cyclic AMP, 3.3 to 20 μM [*r*-³²P] ATP (4 × 10⁵ c.p.m.), 0.5 μg of the enzyme, 100 μg of histone H2B and compound. The mixture is incubated at 30°C for 5 min. The reaction is terminated by adding 1 mL of ice-cold 20% trichloroacetic acid after adding 500 μg of bovine serum albumin as a carrier protein. The sample is centrifuged at 3000 r.p.m. for 15min, the pellet is resuspended in ice-cold 10% trichloro-acetic acid solution and the centrifugation-resuspension cycle is repeated three times. The final pellet is dissolved in 1 mL of 1 N NaOH and radioactivity is measured with a liquid scintillation counter.

References:

- [1]. Ono-Saito N, et al. H-series protein kinase inhibitors and potential clinical applications. *Pharmacol Ther.* 1999 May-Jun;82(2-3):123-31.
- [2]. Asano T, et al. Mechanism of action of a novel antivasospasm drug, HA1077. *J Pharmacol Exp Ther.* 1987 Jun;241(3):1033-40.
- [3]. Asano T, et al. Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinase. *Br J Pharmacol.* 1989 Dec; 98(4):1091-100.
- [4]. Negoro N, et al. The kinase inhibitor fasudil (HA-1077) reduces intimal hyperplasia through inhibiting migration and enhancing cell loss of vascular smooth muscle cells. *Biochem Biophys Res Commun.* 1999 Aug 19;262(1):211-5.
- [5]. Fukushima M, et al. Fasudil hydrochloride hydrate, a Rho-kinase (ROCK) inhibitor, suppresses collagen production and enhances collagenase activity in hepatic stellate cells. *Liver Int.* 2005 Aug;25(4):829-38.
- [6]. Zhang J, et al. Inhibition of the activity of Rho-kinase reduces cardiomyocyte apoptosis in heart ischemia/reperfusion via suppressing JNK-mediated AIF translocation. *Clin Chim Acta.* 2009 Mar;401(1-2):76-80.
- [7]. Sun X, et al. The selective Rho-kinase inhibitor Fasudil is protective and therapeutic in experimental autoimmune encephalomyelitis. *J Neuroimmunol.* 2006 Nov;180(1-2):126-34.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA